Keeping Track: FDA Starts November With A Bang
Executive Summary
The latest drug development news and highlights from our FDA Performance Tracker.
You may also be interested in...
Finance Watch: Phathom IPO Meets Pricing Goal; Cabaletta, TFF Offerings Go Low
Public Company Edition: Phathom went public in the US within proposed pricing terms, but Cabaletta’s IPO went to market below a proposed range, while TFF launched in line with earlier plans. Also, Principia’s FOPO raises $210m and Trillium restructures.
AstraZeneca’s Farxiga Approval In Heart Failure A First For SGLT2 Inhibitors
Farxiga, with a new indication to prevent hospitalization for heart failure in type 2 diabetes patients, is the first drug among the SGLT2 class to gain this indication outside of diabetics with renal disease.
Keeping Track: US FDA, Industry Roar Into Fourth Quarter With Bevy Of Regulatory Announcements
The latest drug development news and highlights from our US FDA Performance Tracker.